In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DMEPOS Prior Authorization Rule Aims To Tackle Fraud, Unnecessary Use

This article was originally published in The Gray Sheet

Executive Summary

A new CMS rule establishes a process for requiring prior authorization for durable medical equipment, prosthetics, orthotics and supplies to tackle fraud and unnecessary use of such products.

You may also be interested in...



CMS Will Require Prior Authorization For 31 Power Wheelchair Types

The US Medicare agency announced will require prior authorization for 31 types of power wheelchairs in an update to its list of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) that need prior authorization as a condition of payment under Medicare.

Spin-out A Neat Solution For Sanofi’s Manufacturing Millstone

Stada Grabs GSK Brands In Key EU Markets

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales in excess of €100m.

Topics

UsernamePublicRestriction

Register

MT034569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel